Evidence explorer
Every claim we hold, and how far we can stand behind it.
142 claims across 39 products. 28% are confirmed against the source text by the evidence gate; 39% come from a class with no vendor interest. Everything below is browsable, filterable, and available as JSON.
What this corpus is made of
| Evidence class | Claims | Confirmed | What it can support |
|---|---|---|---|
| Peer-reviewed study | 19 | 5 | Reviewed before publication; assess study quality, funding, conflicts, and relevance to your setting. |
| Regulatory filing | 4 | 0 | A statement made to a regulator, where being wrong has consequences. |
| Independent report | 32 | 9 | Reporting outside a vendor publication; assess underlying data, sponsorship, and conflicts separately. |
| Customer case | 4 | 3 | A real deployment, but selected and framed by someone with an interest. |
| Press release | 63 | 22 | The vendor's own announcement. Useful for dates and facts, not for outcomes. |
| Vendor page | 20 | 1 | Marketing copy. Establishes what is claimed, never that it is true. |
Showing 1 of 1 matching claims (142 in the full corpus) · 0% of this selection is confirmed · clear filters
PLATFORM trial (JACC 2015): in 584 patients with suspected coronary disease, FFRCT-guided care reduced mean total medical costs by 32% in the planned-invasive stratum versus usual care ($7,343 vs $10,734; p<0.0001) over 90-day follow-up.
Provenance
- Claim ID
- clm_d313d88fef3ff93bd06f
- Version
- 1
- Workflow
- Imaging & Diagnostic AI
- Dimension
- evidence strength
- Retrieved
- 2026-08-27
- Reviewer
- healthit-gate-v1
- Source URL
- https://doi.org/10.1016/j.jacc.2015.09.051